Molbio broadens diagnostics with radiology and digital pathology
Key highlights
- Molbio links ProRAD X-ray screening with Truenat RT-PCR confirmation for tuberculosis testing.
- OptraSCAN’s OS-Ultra scanner range covers 80 to 480 slides and is stated to scan in under 60 seconds.
- Molbio operates 6 manufacturing facilities across 4 locations, including radiology production in Bengaluru and pathology-scanner production in Pune.
- Molbio has 34 human assays across 22 diseases in the Truenat pipeline.
powered by IRIS

Molbio is broadening beyond molecular testing through its Prognosys radiology acquisition and OptraSCAN pathology investment, pairing ProRAD tuberculosis X-ray screening with Truenat reverse transcription-polymerase chain reaction (RT-PCR) confirmation and adding digital pathology systems with 80-to-480-slide configurations that Molbio says scan in under 60 seconds.
Know Molbio Diagnostics inside out
Results, valuation, peers and who's buying, in one view.
How does Prognosys expand Molbio’s diagnostic offering?
Prognosys expands Molbio’s offering by adding digital radiology imaging devices, including an ultra-portable X-ray device pipeline. Molbio describes Prognosys Medical Systems as a Molbio company with a United States Food and Drug Administration (US FDA)-approved range of digital imaging solutions across various X-ray systems. The presentation frames the acquisition as a step to enhance digital radiology capabilities within its universal-access portfolio.
The disclosed use case combines two diagnostic mechanisms for tuberculosis (TB). Prognosys’s ProRAD is positioned for X-ray screening of TB, while Truenat is the RT-PCR confirmatory test. Molbio therefore presents imaging and molecular testing as sequential parts of an end-to-end TB workflow, rather than presenting ProRAD as a replacement for Truenat.
TB is a significant segment of the point-of-care infectious-disease testing market described by Molbio. The presentation reports 170.7 million TB point-of-care tests in calendar year 2025 (CY25), compared with 251.8 million tests for tropical diseases. Molbio lists commercialised tests for TB and tropical diseases, as well as for human papillomavirus, hepatitis B virus and hepatitis C virus.
The difference between TB and tropical diseases is relevant to the proposed radiology linkage. Tropical diseases had 81.1 million more tests than TB in CY25, but the Prognosys slide identifies TB as the specific screening-and-confirmation pathway for ProRAD and Truenat. The presentation does not disclose clinical-performance measures, installations or revenue from that combined workflow.
What does OptraSCAN add to Molbio’s portfolio?
OptraSCAN adds digital pathology scanners, artificial intelligence (AI)-powered analysis tools and telepathology services to Molbio’s portfolio. Molbio says these tools enable remote consultations and collaboration, broadening the product range from molecular test systems into pathology image capture, analysis, storage and remote review.
The scanner line spans several pathology workflows and capacities. The OS-SiX Brightfield Scanner handles 6 slides, the OS-Lite Brightfield Scanner handles 15 slides, and the OS-Ultra Brightfield Scanner is offered in configurations from 80 to 480 slides. The portfolio also includes the OS-FiA Cytology Scanner, OS-FS Frozen Sections Scanner and OS-FLi fluorescence and brightfield system.
The OS Ultra Series is available in 80-, 160-, 240-, 320-, 400- and 480-slide versions, compared with 15 slides for the OS 15 Scanner. Molbio says the Ultra Series scans in under 60 seconds without compromising image quality. It also says OS Lite is wirelessly enabled for storage, archiving and management of digital images and metadata.
OptraSCAN received US FDA 510(k) clearance, identified in the presentation as K260755, for its OptraScan System. Molbio describes its investment in the US-based company as supporting global reach and diversification. The supplied presentation does not disclose the investment amount, ownership interest, transaction date, revenue contribution or number of installed systems.
Got a follow-up? Ask IRIS
Where are Molbio’s radiology and pathology products made?
Molbio says radiology devices are made at its 2 Bengaluru facilities, while digital pathology scanners are made at its 1 Pune facility. These sites are part of a 6-facility footprint across 4 locations. The other 3 sites support Truenat: 2 Goa facilities manufacture test kits and 1 Visakhapatnam facility manufactures devices and test-kit components.
The location split separates radiology and pathology manufacturing from the principal Truenat production sites. Bengaluru makes both test-kit components and radiology devices, while Pune makes digital pathology scanners. Molbio says its geographically diversified manufacturing footprint is designed to support continuity, redundancy and scalability across key product categories.
The quantified capacity disclosed in the presentation remains specific to Truenat. Molbio reports annual capacity of 39 million Truenat test kits and 5,400 Truenat devices. In fiscal year 2026 (FY26), test-kit utilisation was 58.25%, compared with 42.30% for devices.
Test-kit utilisation was 15.95 percentage points higher than device utilisation in FY26. Molbio says it manufactures core products in-house and uses electronics manufacturing services partners for Truenat device assembly as needed. It does not provide comparable capacity or utilisation figures for radiology devices or pathology scanners.
Molbio also reports 221 quality assurance and quality control professionals and says test kits, reagents and cartridges receive 100% quality-control checks before dispatch. Its presentation does not separately quantify quality personnel, checks or output for Prognosys radiology products and OptraSCAN scanners. That leaves the disclosed manufacturing detail more developed for Truenat than for the newer modalities.
What is Molbio planning after these additions?
Molbio plans to grow inorganically through strategic acquisitions and alliances, citing Prognosys and OptraSCAN as capability-expansion examples. It also lists collaborations with HealSea, Xcyton, UE LifeSciences, Stellar and Testi Technologies. The presentation gives no transaction values, revenue targets, closing dates or commercial terms for these arrangements.
Geographically, management says Molbio is focused on enhancing exports, particularly in Africa and Southeast Asia, where it has a presence. It also plans to enter the European Union and US markets with a portfolio of Molbio products. These are stated plans, not disclosures of completed market entries or sales in those regions.
The company’s development plan extends beyond its current infectious-disease test range. Molbio says it will use advanced multiplex polymerase chain reaction technologies to develop point-of-care platforms for immunochemistry, hematology, histopathology, biochemistry and antimicrobial resistance. The stated plan covers both communicable and non-communicable diseases.
Molbio reports 34 human assays covering 22 diseases in the Truenat pipeline, plus a veterinary rabies assay and 6 veterinary assays. Its research and development pipeline includes Trueamp Mini, which analyses up to 16 targets per run, Truepoc for TB testing in sputum and tongue swabs, and Truecyte, an AI-powered digital pathology system for human and veterinary use.
Conclusion
Molbio’s radiology and pathology moves add X-ray screening and digital-image-based pathology to a portfolio centred on molecular testing. The manufacturing footprint places radiology production in Bengaluru and pathology-scanner production in Pune, while the stated TB pathway connects ProRAD screening to Truenat molecular confirmation.
What to watch next is execution against management’s plans to enter the European Union and US, enhance exports in Africa and Southeast Asia, and progress 34 human assays across 22 diseases in the Truenat pipeline. Molbio also identifies an EDGE innovation programme and a proposed centre of excellence in Bengaluru, but the presentation provides no timetable, spending figure or commercial target for either initiative.


